Regulatory Polymorphisms and their Contribution to Interindividual Differences in the Expression of Enzymes Influencing Drug and Toxicant Disposition

REFERENCES

• Abdel-Rahman S. Z., Ammenheuser M. M., Omiecinski C. J., Wickliffe J. K., Rosenblatt J. I., Ward J. B., Jr. Variability in human sensitivity to 1,3-butadiene: influence of polymorphisms in the 5′-flanking region of the microsomal epoxide hydrolase gene (EPHX1). Toxicol. Sci. 2005; 85: 624–631
   PubMed Web of Science ®Google Scholar
• Aklillu E., Carrillo J. A., Makonnen E., Hellman K., Pitarque M., Bertilsson L., Ingelman-Sundberg M. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol. Pharmacol. 2003; 64: 659–669
   PubMed Web of Science ®Google Scholar
• Allerston C. K., Shimizu M., Fujieda M., Shephard E. A., Yamazaki H., Phillips I. R. Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenet. Genomics 2007; 17: 827–839
   PubMed Web of Science ®Google Scholar
• Alves S., Amorim A., Ferreira F., Prata M. J. Influence of the variable number of tandem repeats located in the promoter region of the thiopurine methyltransferase gene on enzymatic activity. Clin. Pharmacol. Ther. 2001; 70: 165–174
   PubMed Web of Science ®Google Scholar
• Amirimani B., Ning B., Deitz A. C., Weber B. L., Kadlubar F. F., Rebbeck T. R. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ. Mol. Mutagen. 2003; 42: 299–305
   PubMed Web of Science ®Google Scholar
• Andersson T., Miners J. O., Veronese M. E., Tassaneeyakul W., Meyer U. A., Birkett D. J. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br. J. Clin. Pharmacol. 1993; 36: 521–530
   PubMed Web of Science ®Google Scholar
• Ando Y., Saka H., Ando M., Sawa T., Muro K., Ueoka H., Yokoyama A., Saitoh S., Shimokata K., Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000; 60: 6921–6926
   PubMed Web of Science ®Google Scholar
• Anglicheau D., Verstuyft C., Laurent-Puig P., Becquemont L., Schlageter M. H., Cassinat B., Beaune P., Legendre C., Thervet E. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 2003; 14: 1889–1896
   PubMed Web of Science ®Google Scholar
• Anttila S., Lei X. D., Elovaara E., Karjalainen A., Sun W., Vainio H., Hankinson O. An uncommon phenotype of poor inducibility of CYP1A1 in human lung is not ascribable to polymorphisms in the AHR, ARNT, or CYP1A1 genes. Pharmacogenetics 2000; 10: 741–751
   PubMedGoogle Scholar
• Ariyoshi N., Miyamoto M., Umetsu Y., Kunitoh H., aka-Akita H., Sawamura Y., Yokota J., Nemoto N., Sato K., Kamataki T. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol. Biomarkers Prev. 2002; 11: 890–894
   PubMed Web of Science ®Google Scholar
• Bacsi K., Kosa J. P., Borgulya G., Balla B., Lazary A., Nagy Z., Horvath C., Speer G., Lakatos P. CYP3A7*1C polymorphism, serum dehydroepiandrosterone sulfate level, and bone mineral density in postmenopausal women. Calcif. Tissue Int. 2007; 80: 154–159
   PubMed Web of Science ®Google Scholar
• Bertz R. J., Granneman G. R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin. Pharmacokinet. 1997; 32: 210–258
   PubMed Web of Science ®Google Scholar
• Beutler E., Gelbart T., Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc. Natl. Acad. Sci. USA 1998; 95: 8170–8174
   PubMed Web of Science ®Google Scholar
• Blackburn A. C., Woollatt E., Sutherland G. R., Board P. G. Characterization and chromosome location of the gene GSTZ1 encoding the human Zeta class glutathione transferase and maleylacetoacetate isomerase. Cytogenet. Cell Genet. 1998; 83: 109–114
   PubMedGoogle Scholar
• Blaisdell J., Jorge-Nebert L. F., Coulter S., Ferguson S. S., Lee S. J., Chanas B., Xi T., Mohrenweiser H., Ghanayem B., Goldstein J. A. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 2004; 14: 527–537
   PubMedGoogle Scholar
• Board P. G., Coggan M., Chelvanayagam G., Easteal S., Jermiin L. S., Schulte G. K., Danley D. E., Hoth L. R., Griffor M. C., Kamath A. V., Rosner M. H., Chrunyk B. A., Perregaux D. E., Gabel C. A., Geoghegan K. F., Pandit J. Identification, characterization, and crystal structure of the Omega class glutathione transferases. J. Biol. Chem. 2000; 275: 24798–24806
   PubMed Web of Science ®Google Scholar
• Bosma P. J., Chowdhury J. R., Bakker C., Gantla S., de Boer A., Oostra B. A., Lindhout D., Tytgat G. N., Jansen P. L., Oude Elferink R. P. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 1995; 333: 1171–1175
   PubMed Web of Science ®Google Scholar
• Bredschneider M., Klein K., Murdter T. E., Marx C., Eichelbaum M., Nussler A. K., Neuhaus P., Zanger U. M., Schwab M. Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: consequences for enzyme expression and busulfan conjugation. Clin. Pharmacol. Ther. 2002; 71: 479–487
   PubMed Web of Science ®Google Scholar
• Buckland P. R., Hoogendoorn B., Coleman S. L., Guy C. A., Smith S. K., O'Donovan M. C. Strong bias in the location of functional promoter polymorphisms. Hum. Mutat. 2005; 26: 214–223
   PubMed Web of Science ®Google Scholar
• Burk O., Tegude H., Koch I., Hustert E., Wolbold R., Glaeser H., Klein K., Fromm M. F., Nuessler A. K., Neuhaus P., Zanger U. M., Eichelbaum M., Wojnowski L. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J. Biol. Chem. 2002; 277: 24280–24288
   PubMed Web of Science ®Google Scholar
• Calado R. T., Falcao R. P., Garcia A. B., Gabellini S. M., Zago M. A., Franco R. F. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. Haematologica 2002; 87: 564–568
   PubMed Web of Science ®Google Scholar
• Carlini L. E., Meropol N. J., Bever J., Andria M. L., Hill T., Gold P., Rogatko A., Wang H., Blanchard R. L. UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin. Cancer Res. 2005; 11: 1226–1236
   PubMed Web of Science ®Google Scholar
• Carrier J. S., Turgeon D., Journault K., Hum D. W., Belanger A. Isolation and characterization of the human UGT2B7 gene. Biochem. Biophys. Res. Commun. 2000; 272: 616–621
   PubMed Web of Science ®Google Scholar
• Chen H. J., Tian H., Edenberg H. J. Natural haplotypes in the regulatory sequences affect human alcohol dehydrogenase 1C (ADH1C) gene expression. Hum. Mutat. 2005; 25: 150–155
   PubMed Web of Science ®Google Scholar
• Chou W. Y., Stewart M. J., Carr L. G., Zheng D., Stewart T. R., Williams A., Pinaire J., Crabb D. W. An A/G polymorphism in the promoter of mitochondrial aldehyde dehydrogenase (ALDH2): effects of the sequence variant on transcription factor binding and promoter strength. Alcohol Clin. Exp. Res. 1999; 23: 963–968
   PubMed Web of Science ®Google Scholar
• Code E. L., Crespi C. L., Penman B. W., Gonzalez F. J., Chang T. K., Waxman D. J. Human cytochrome P4502B6 – Interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab. Dispos. 1997; 25: 985–993
   PubMed Web of Science ®Google Scholar
• Coffman B. L., Rios G. R., King C. D., Tephly T. R. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metab Dispos. 1997; 25: 1–4
   PubMed Web of Science ®Google Scholar
• Coles B. F., Kadlubar F. F. Detoxification of electrophilic compounds by glutathione S-transferase catalysis: determinants of individual response to chemical carcinogens and chemotherapeutic drugs?. Biofactors 2003; 17: 115–130
   PubMed Web of Science ®Google Scholar
• Coles B. F., Kadlubar F. F. Human alpha class glutathione S-transferases: genetic polymorphism, expression, and susceptibility to disease. Methods Enzymol. 2005; 401: 9–42
   PubMed Web of Science ®Google Scholar
• Coles B. F., Morel F., Rauch C., Huber W. W., Yang M., Teitel C. H., Green B., Lang N. P., Kadlubar F. F. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001; 11: 663–669
   PubMedGoogle Scholar
• Collins F. S., Green E. D., Guttmacher A. E., Guyer M. S. A vision for the future of genomics research. Nature 2003; 422: 835–847
   PubMed Web of Science ®Google Scholar
• Coulthard S., Hogarth L. The thiopurines: an update. Invest New Drugs 2005; 23: 523–532
   PubMed Web of Science ®Google Scholar
• Desta Z., Zhao X., Shin J. G., Flockhart D. A. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 2002; 41: 913–958
   PubMed Web of Science ®Google Scholar
• Dickson P. A., James M. R., Heath A. C., Montgomery G. W., Martin N. G., Whitfield J. B., Birley A. J. Effects of variation at the ALDH2 locus on alcohol metabolism, sensitivity, consumption, and dependence in Europeans. Alcohol Clin. Exp. Res. 2006; 30: 1093–1100
   PubMed Web of Science ®Google Scholar
• Djebli N., Picard N., Rerolle J. P., Le Meur Y., Marquet P. Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. Pharmacogenet. Genomics 2007; 17: 321–330
   PubMed Web of Science ®Google Scholar
• Duguay Y., Baar C., Skorpen F., Guillemette C. A novel functional polymorphism in the uridine diphosphate-glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clin. Pharmacol. Ther. 2004a; 75: 223–233
   PubMed Web of Science ®Google Scholar
• Duguay Y., McGrath M., Lepine J., Gagne J. F., Hankinson S. E., Colditz G. A., Hunter D. J., Plante M., Tetu B., Belanger A., Guillemette C., De V. I. The functional UGT1A1 promoter polymorphism decreases endometrial cancer risk. Cancer Res. 2004b; 64: 1202–1207
   PubMed Web of Science ®Google Scholar
• Edenberg H. J. The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde dehydrogenase variants. Alcohol Res. Health 2007; 30: 5–13
   PubMedGoogle Scholar
• Edenberg H. J., Bosron W. F. Alcohol dehydrogenases. Comprehensive toxicology: Biotransformation, F.P. Guengerich. Pergamon, New York 1997; 119–131
   Google Scholar
• Edenberg H. J., Jerome R. E., Li M. Polymorphism of the human alcohol dehydrogenase 4 (ADH4) promoter affects gene expression. Pharmacogenetics 1999; 9: 25–30
   PubMedGoogle Scholar
• Edenberg H. J., Xuei X., Chen H. J., Tian H., Wetherill L. F., Dick D. M., Almasy L., Bierut L., Bucholz K. K., Goate A., Hesselbrock V., Kuperman S., Nurnberger J., Porjesz B., Rice J., Schuckit M., Tischfield J., Begleiter H., Foroud T. Association of alcohol dehydrogenase genes with alcohol dependence: a comprehensive analysis. Hum. Mol. Genet. 2006; 15: 1539–1549
   PubMed Web of Science ®Google Scholar
• Eichelbaum M., Ingelman-Sundberg M., Evans W. E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 2006; 57: 119–137
   PubMed Web of Science ®Google Scholar
• Evans W. E., Relling M. V. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487–491
   PubMed Web of Science ®Google Scholar
• Fairbrother K. S., Grove J., de Waziers I., Steimel D. T., Day C. P., Crespi C. L., Daly A. K. Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics 1998; 8: 543–552
   PubMedGoogle Scholar
• Fang J. L., Lazarus P. Correlation between the UDP-glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol. Biomarkers Prev. 2004; 13: 102–109
   PubMed Web of Science ®Google Scholar
• Ferraris A., D'Amato G., Nobili V., Torres B., Marcellini M., Dallapiccola B. Combined test for UGT1A1 -3279T—>G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet. Test. 2006; 10: 121–125
   PubMedGoogle Scholar
• Fertrin K. Y., Goncalves M. S., Saad S. T., Costa F. F. Frequencies of UDP-glucuronosyltransferase 1 (UGT1A1) gene promoter polymorphisms among distinct ethnic groups from Brazil. Am. J. Med. Genet. 2002; 108: 117–119
   PubMed Web of Science ®Google Scholar
• Fessing M. Y., Krynetski E. Y., Zambetti G. P., Evans W. E. Functional characterization of the human thiopurine S-methyltransferase (TPMT) gene promoter. Eur. J Biochem. 1998; 256: 510–517
   PubMedGoogle Scholar
• Freimuth R. R., Wiepert M., Chute C. G., Wieben E. D., Weinshilboum R. M. Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes. Pharmacogenomics J. 2004; 4: 54–65
   PubMed Web of Science ®Google Scholar
• Gaedigk A., Ryder D. L., Bradford L. D., Leeder J. S. CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. Clin. Chem. 2003; 49: 1008–1011
   PubMed Web of Science ®Google Scholar
• Gaedigk A., Spielberg S. P., Grant D. M. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142–153
   PubMedGoogle Scholar
• Garrod A. E., Oxon M. D. The incidence of alkaptonuria: A study in chemical individuality. Lancet 1902; 1616–1620
   Google Scholar
• Girard H., Court M. H., Bernard O., Fortier L. C., Villeneuve L., Hao Q., Greenblatt D. J., Von Moltke L. L., Perussed L., Guillemette C. Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver. Pharmacogenetics 2004; 14: 501–515
   PubMedGoogle Scholar
• Glatt H., Meinl W. Pharmacogenetics of soluble sulfotransferases (SULTs). Naunyn Schmiedebergs Arch. Pharmacol. 2004; 369: 55–68
   PubMed Web of Science ®Google Scholar
• Goldstein J. A., Faletto M. B., Romkes-Sparks M., Sullivan T., Kitareewan S., Raucy J. L., Lasker J. M., Ghanayem B. I. Evidence that CYP2C19 is the major (S)-mephenytoin 4′- hydroxylase in humans. Biochemistry 1994; 33: 1743–1752
   PubMed Web of Science ®Google Scholar
• Goodwin B., Moore L. B., Stoltz C. M., McKee D. D., Kliewer S. A. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol. Pharmacol. 2001; 60: 427–431
   PubMed Web of Science ®Google Scholar
• Greenberg B. D., Tolliver T. J., Huang S. J., Li Q., Bengel D., Murphy D. L. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am. J. Med. Genet. 1999; 88: 83–87
   PubMed Web of Science ®Google Scholar
• Greuet J., Pichard L., Bonfils C., Domergue J., Maurel P. The fetal specific gene CYP3A7 is inducible by rifampicin in adult human hepatocytes in primary culture. Biochem. Biophys. Res. Commun 1996; 225: 689–694
   PubMed Web of Science ®Google Scholar
• Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003; 3: 136–158
   PubMed Web of Science ®Google Scholar
• Guillemette C., Millikan R. C., Newman B., Housman D. E. Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res. 2000; 60: 950–956
   PubMed Web of Science ®Google Scholar
• Guindalini C., Scivoletto S., Ferreira R. G., Breen G., Zilberman M., Peluso M. A., Zatz M. Association of genetic variants in alcohol dehydrogenase 4 with alcohol dependence in Brazilian patients. Am. J. Psych. 2005; 162: 1005–1007
   PubMed Web of Science ®Google Scholar
• Guy C. A., Hoogendoorn B., Smith S. K., Coleman S., O'Donovan M. C., Buckland P. R. Promoter polymorphisms in glutathione-S-transferase genes affect transcription. Pharmacogenetics 2004; 14: 45–51
   PubMedGoogle Scholar
• Haberl M., Anwald B., Klein K., Weil R., Fuss C., Gepdiremen A., Zanger U. M., Meyer U. A., Wojnowski L. Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenet. Genomics 2005; 15: 609–624
   PubMed Web of Science ®Google Scholar
• Han X. M., Ouyang D. S., Chen X. P., Shu Y., Jiang C. H., Tan Z. R., Zhou H. H. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br. J Clin. Pharmacol. 2002; 54: 540–543
   PubMed Web of Science ®Google Scholar
• Hariri A. R., Drabant E. M., Weinberger D. R. Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing. Biol. Psych. 2006; 59: 888–897
   PubMed Web of Science ®Google Scholar
• Hashizume T., Imaoka S., Mise M., Terauchi Y., Fujii T., Miyazaki H., Kamataki T., Funae Y. Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes. J Pharmacol. Exp. Ther. 2002; 300: 298–304
   PubMed Web of Science ®Google Scholar
• Hassett C., Aicher L., Sidhu J. S., Omiecinski C. J. Human microsomal epoxide hydrolase: Genetic polymorphism and functional expression in vitro of amino acid variants. Hum. Mol. Genet. 1994; 3: 421–428
   PubMed Web of Science ®Google Scholar
• Hayes J. D., Pulford D. J. The glutatione S-transferase super-gene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprevention and drug resistance. Crit. Rev. Biochem. Mol. Biol. 1995; 30: 445–600
   PubMed Web of Science ®Google Scholar
• Hedberg J. J., Backlund M., Stromberg P., Lonn S., Dahl M. L., Ingelman-Sundberg M., Hoog J. O. Functional polymorphism in the alcohol dehydrogenase 3 (ADH3) promoter. Pharmacogenetics 2001; 11: 815–824
   PubMedGoogle Scholar
• Her C., Wood T. C., Eichler E. E., Mohrenweiser H. W., Ramagli L. S., Siciliano M. J., Weinshilboum R. M. Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. Genomics 1998; 53: 284–295
   PubMed Web of Science ®Google Scholar
• Hernandez D., Janmohamed A., Chandan P., Phillips I. R., Shephard E. A. Organization and evolution of the flavin-containing monooxygenase genes of human and mouse: identification of novel gene and pseudogene clusters. Pharmacogenetics 2004; 14: 117–130
   PubMedGoogle Scholar
• Hesse L. M., He P., Krishnaswamy S., Hao Q., Hogan K., Von Moltke L. L., Greenblatt D. J., Court M. H. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225–238
   PubMedGoogle Scholar
• Hines R. N. Developmental and tissue-specific expression of human flavin-containing monooxygenase 1 and 3. Expert Opin. Drug Metabol.Toxicol. 2006; 2: 41–49
   PubMed Web of Science ®Google Scholar
• Hines R. N., Luo Z., Hopp K. A., Cabacungan E. T., Koukouritaki S. B., McCarver D. G. Genetic variability at the human FMO1 locus: Significance of a yin yang 1 element polymorphism (FMO1*6). J. Pharmacol. Exp. Ther. 2003; 306: 1210–1218
   PubMed Web of Science ®Google Scholar
• Holthe M., Rakvag T. N., Klepstad P., Idle J. R., Kaasa S., Krokan H. E., Skorpen F. Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients. Pharmacogenom. J. 2003; 3: 17–26
   PubMed Web of Science ®Google Scholar
• Hoogendoorn B., Coleman S. L., Guy C.A., Smith K., Bowen T., Buckland P. R., O'Donovan M. C. Functional analysis of human promoter polymorphisms. Hum. Mol. Genet. 2003; 12: 2249–2254
   PubMed Web of Science ®Google Scholar
• Hsu L. C., Bendel R. E., Yoshida A. Genomic structure of the human mitochondrial aldehyde dehydrogenase gene. Genomics 1988; 2: 57–65
   PubMed Web of Science ®Google Scholar
• Hu X. Z., Rush A. J., Charney D., Wilson A. F., Sorant A. J., Papanicolaou G. J., Fava M., Trivedi M. H., Wisniewski S. R., Laje G., Paddock S., McMahon F. J., Manji H., Lipsky R. H. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch. Gen. Psychiatry 2007; 64: 783–792
   PubMed Web of Science ®Google Scholar
• Hu Y., Hakkola J., Oscarson M., Ingelman-Sundberg M. Structural and functional characterization of the 5′-flanking region of the rat and human cytochrome P4502E1 genes: Identification of a polymorphic repeat in the human gene. Biochem. Biophys. Res. Commun. 1999; 263: 286–293
   PubMed Web of Science ®Google Scholar
• Innocenti F., Grimsley C., Das S., Ramirez J., Cheng C., Kuttab-Boulos H., Ratain M. J., Di R. A. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 2002; 12: 725–733
   PubMedGoogle Scholar
• Innocenti F., Iyer L., Ratain M. J. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab. Dispos. 2001; 29: 596–600
   PubMed Web of Science ®Google Scholar
• Iolascon A., Faienza M. F., Centra M., Storelli S., Zelante L., Savoia A. (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome. Haematologica 1999; 84: 106–109
   PubMed Web of Science ®Google Scholar
• Itoga S., Nomura F., Makino Y., Tomonaga T., Shimada H., Ochiai T., Iizasa T., Baba M., Fujisawa T., Harada S. Tandem repeat polymorphism of the CYP2E1 gene: An association study with esophageal cancer and lung cancer. Alcohol. Clin. Exp. Res. 2002; 26: 15S–19S
   PubMed Web of Science ®Google Scholar
• Iyer L., Das S., Janisch L., Wen M., Ramirez J., Karrison T., Fleming G.F., Vokes E. E., Schilsky R. L., Ratain M. J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenom. J. 2002; 2: 43–47
   PubMedGoogle Scholar
• Iyer L., Hall D., Das S., Mortell M. A., Ramirez J., Kim S., Di R. A., Ratain M. J. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 1999; 65: 576–582
   PubMed Web of Science ®Google Scholar
• Ji Y., Moon I., Zlatkovic J., Salavaggione O. E., Thomae B. A., Eckloff B. W., Wieben E. D., Schaid D. J., Weinshilboum R. M. Human hydroxysteroid sulfotransferase SULT2B1 pharmacogenomics: gene sequence variation and functional genomics. J Pharmacol. Exp. Ther. 2007; 322: 529–540
   PubMed Web of Science ®Google Scholar
• Jin C., Miners J. O., Lillywhite K. J., Mackenzie P. I. Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol. Exp. Ther. 1993; 264: 475–479
   PubMed Web of Science ®Google Scholar
• Kanaoka Y., Fujimori K., Kikuno R., Sakaguchi Y., Urade Y., Hayaishi O. Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. Eur. J. Biochem. 2000; 267: 3315–3322
   PubMedGoogle Scholar
• Kellermann G., Luyten-Kellermann M., Shaw C. R. Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. Am. J. Hum. Genet. 1973; 25: 327–331
   PubMed Web of Science ®Google Scholar
• Kim D. K., Lim S. W., Lee S., Sohn S. E., Kim S., Hahn C. G., Carroll B. J. Serotonin transporter gene polymorphism and antidepressant response. Neuroreport 2000; 11: 215–219
   PubMed Web of Science ®Google Scholar
• Kim M. J., Bertino J. S., Jr., Gaedigk A., Zhang Y., Sellers E. M., Nafziger A. N. Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker. Clin. Pharmacol. Ther. 2002; 72: 192–199
   PubMed Web of Science ®Google Scholar
• King B. P., Khan T. I., Aithal G. P., Kamali F., Daly A. K. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 2004; 14: 813–822
   PubMedGoogle Scholar
• King C. D., Rios G. R., Green M. D., Tephly T. R. UDP-glucuronosyltransferases. Curr. Drug Metab. 2000; 1: 143–161
   PubMed Web of Science ®Google Scholar
• King L. M., Gainer J. V., David G. L., Dai D., Goldstein J. A., Brown N. J., Zeldin D. C. Single nucleotide polymorphisms in the CYP2J2 and CYP2C8 genes and the risk of hypertension. Pharmacogenet. Genomics 2005; 15: 7–13
   PubMedGoogle Scholar
• Kiyotani K., Yamazaki H., Fujieda M., Iwano S., Matsumura K., Satarug S., Ujjin P., Shimada T., Guengerich F. P., Parkinson A., Honda G., Nakagawa K., Ishizaki T., Kamataki T. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003; 13: 689–695
   PubMedGoogle Scholar
• Klick D. E., Hines R. N. Mechanisms regulating human FMO3 transcription. Drug Metab. Rev. 2007; 39: 419–442
   PubMed Web of Science ®Google Scholar
• Kohle C., Mohrle B., Munzel P. A., Schwab M., Wernet D., Badary O. A., Bock K. W. Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians. Biochem. Pharmacol. 2003; 65: 1521–1527
   PubMed Web of Science ®Google Scholar
• Komori M., Nishio K., Kitada M., Shiramatsu K., Muroya K., Soma M., Nagashima K., Kamataki T. Fetus-specific expression of a form of cytochrome P-450 in human livers. Biochemistry 1990; 29: 4430–4433
   PubMed Web of Science ®Google Scholar
• Koukouritaki S. B., Hines R. N. Flavin-containing monooxygenase genetic polymorphism: impact on chemical metabolism and drug development. Pharmacogenomics 2005a; 6: 807–822
   PubMed Web of Science ®Google Scholar
• Koukouritaki S. B., Poch M. T., Cabacungan E. T., McCarver D. G., Hines R. N. Discovery of novel flavin-containing monooxygenase 3 (FMO3) single nucleotide polymorphisms and functional analysis of upstream haplotype variants. Mol. Pharmacol. 2005b; 68: 383–392
   PubMed Web of Science ®Google Scholar
• Koukouritaki S. B., Poch M. T., Henderson M. C., Siddens L. K., Krueger S. K., Vandyke J. E., Williams D. E., Pajewski N. M., Wang T., Hines R. N. Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol. Exp. Ther. 2007; 320: 266–273
   PubMed Web of Science ®Google Scholar
• Koukouritaki S. B., Simpson P., Yeung C. K., Rettie A. E., Hines R. N. Human hepatic flavin-containing monooxygenase 1 (FMO1) and 3 (FMO3) developmental expression. Pediatric Res. 2002; 51: 236–243
   PubMed Web of Science ®Google Scholar
• Kouri R. E., McKinney C. E., Slomiany D. J., Snodgrass D. R., Wray N. P., McLemore T. L. Positive correlations between high aryl hydrocarbon hydroxylase activity and presence of lung cancer – analysis of cryopreserved lymphocytes. Cancer Res. 1982; 42: 5030–5037
   PubMed Web of Science ®Google Scholar
• Krueger S. K., Williams D. E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 2005; 106: 357–387
   PubMed Web of Science ®Google Scholar
• Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., Watkins P. B., Daly A., Wrighton S.A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Venkataramanan R., Strom S., Thummel K., Boguski M. S., Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 2001; 27: 383–391
   PubMed Web of Science ®Google Scholar
• Kurys G., Ambroziak W., Pietruszko R. Human aldehyde dehydrogenase. Purification and characterization of a third isozyme with low Km for gamma-aminobutyraldehyde. J. Biol. Chem. 1989; 264: 4715–4721
   PubMed Web of Science ®Google Scholar
• Kuypers D. R., Naesens M., Vermeire S., Vanrenterghem Y. The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin. Pharmacol. Ther. 2005; 78: 351–361
   PubMed Web of Science ®Google Scholar
• Lafite P., Andre F., Zeldin D. C., Dansette P. M., Mansuy D. Unusual regioselectivity and active site topology of human cytochrome P450 2J2. Biochemistry 2007; 46: 10237–10247
   PubMed Web of Science ®Google Scholar
• Lamba J., Lamba V., Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug Metab 2005; 6: 369–383
   PubMed Web of Science ®Google Scholar
• Lamba V., Lamba J., Yasuda K., Strom S., Davila J., Hancock M. L., Fackenthal J. D., Rogan P. K., Ring B., Wrighton S. A., Schuetz E. G. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol. Exp. Ther. 2003; 307: 906–922
   PubMed Web of Science ®Google Scholar
• Lampe J. W., Bigler J., Horner N. K., Potter J. D. UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations. Pharmacogenetics 1999; 9: 341–349
   PubMedGoogle Scholar
• Lang T., Klein K., Fisher J., Nüssler A. K., Neuhaus P., Hofmann U., Eichelbaum M., Schwab M., Zanger U. M. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 2001; 11: 399–415
   PubMedGoogle Scholar
• Lankisch T. O., Vogel A., Eilermann S., Fiebeler A., Krone B., Barut A., Manns M. P., Strassburg C. P. Identification and characterization of a functional TATA box polymorphism of the UDP glucuronosyltransferase 1A7 gene. Mol. Pharmacol. 2005; 67: 1732–1739
   PubMed Web of Science ®Google Scholar
• Lee A. J., Conney A. H., Zhu B. T. Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol. Cancer Res. 2003; 63: 6532–6536
   PubMed Web of Science ®Google Scholar
• Lee S. L., Chau G. Y., Yao C. T., Wu C. W., Yin S. J. Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin. Exp. Res. 2006; 30: 1132–1142
   PubMed Web of Science ®Google Scholar
• Lee W. J., Brennan P., Boffetta P., London S. J., Benhamou S., Rannug A., To-Figueras J., Ingelman-Sundberg M., Shields P., Gaspari L., Taioli E. Microsomal epoxide hydrolase polymorphisms and lung cancer risk: a quantitative review. Biomarkers 2002; 7: 230–241
   PubMed Web of Science ®Google Scholar
• Lesch K. P., Bengel D., Heils A., Sabol S. Z., Greenberg B. D., Petri S., Benjamin J., Muller C. R., Hamer D. H., Murphy D. L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996; 274: 1527–1531
   PubMed Web of Science ®Google Scholar
• Levesque E., Delage R., Benoit-Biancamano M. O., Caron P., Bernard O., Couture F., Guillemette C. The impact of UGT1A8, UGT1A9, and UGT2B7 genetic polymorphisms on the pharmacokinetic profile of mycophenolic acid after a single oral dose in healthy volunteers. Clin. Pharmacol. Ther. 2007; 81: 392–400
   PubMed Web of Science ®Google Scholar
• Li M., Edenberg H. J. Function of cis-acting elements in human alcohol dehydrogenase 4 (ADH4) promoter and role of C/EBP proteins in gene expression. DNA Cell Biol. 1998; 17: 387–397
   PubMed Web of Science ®Google Scholar
• Lieber C. S. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab. Rev. 2004; 36: 511–529
   PubMed Web of Science ®Google Scholar
• Lieber C. S., DeCarli L. M. Hepatic microsomal ethanol-oxidizing system. In vitro characteristics and adaptive properties in vivo. J. Biol. Chem. 1970; 245: 2505–2512
   PubMed Web of Science ®Google Scholar
• Lindahl R. Aldehyde dehydrogenases and their role in carcinogenesis. Crit. Rev. Biochem. Mol. Biol. 1992; 27: 283–335
   PubMed Web of Science ®Google Scholar
• Little K. Y., McLaughlin D. P., Zhang L., Livermore C. S., Dalack G. W., McFinton P. R., DelProposto Z. S., Hill E., Cassin B. J., Watson S. J., Cook E. H. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am. J. Psych. 1998; 155: 207–213
   PubMed Web of Science ®Google Scholar
• Little K. Y., Zhang L., Cook E. Fluoxetine-induced alterations in human platelet serotonin transporter expression: serotonin transporter polymorphism effects. J. Psych. Neurosci. 2006; 31: 333–339
   PubMed Web of Science ®Google Scholar
• Lovlie R., Daly A. K., Matre G. E., Molven A., Steen V. M. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics 2001; 11: 45–55
   PubMedGoogle Scholar
• Luo X., Kranzler H. R., Zuo L., Lappalainen J., Yang B. Z., Gelernter J. ADH4 gene variation is associated with alcohol dependence and drug dependence in European Americans: results from HWD tests and case-control association studies. Neuropsychopharmacology 2006; 31: 1085–1095
   PubMed Web of Science ®Google Scholar
• Mackenzie P. I., Bock K. W., Burchell B., Guillemette C., Ikushiro S., Iyanagi T., Miners J. O., Owens I. S., Nebert D. W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics 2005; 15: 677–685
   PubMed Web of Science ®Google Scholar
• Mackenzie P. I., Owens I. S., Burchell B., Bock K. W., Bairoch A., Bélanger A., Fournel-Gigleux S., Green M., Hum D. W., Iyanagi T., Lancet D., Louisot P., Magdalou J., Chowdhury J. R., Ritter J. K., Schachter H., Tephly T. R., Tipton K. F., Nebert D. W. The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics 1997; 7: 255–269
   PubMedGoogle Scholar
• Marinaki A. M., Arenas M., Khan Z. H., Lewis C. M., Shobowale-Bakre e., Escuredo E., Fairbanks L. D., Mayberry J. F., Wicks A. C., Ansari A., Sanderson J., Duley J. A. Genetic determinants of the thiopurine methyltransferase intermediate activity phenotype in British Asians and Caucasians. Pharmacogenetics 2003; 13: 97–105
   PubMedGoogle Scholar
• Matsumoto S., Hirama T., Matsubara T., Nagata K., Yamazoe Y. Involvement of CYP2J2 on the intestinal first-pass metabolism of antihistamine drug, astemizole. Drug Metab. Dispos. 2002; 30: 1240–1245
   PubMed Web of Science ®Google Scholar
• Matsumura K., Saito T., Takahashi Y., Ozeki T., Kiyotani K., Fujieda M., Yamazaki H., Kunitoh H., Kamataki T. Identification of a novel polymorphic enhancer of the human CYP3A4 gene. Mol. Pharmacol. 2004; 65: 326–334
   PubMed Web of Science ®Google Scholar
• Matsuno K., Kubota T., Matsukura Y., Ishikawa H., Iga T. Genetic analysis of glutathione S-transferase A1 and T1 polymorphisms in a Japanese population. Clin. Chem. Lab Med. 2004; 42: 560–562
   PubMed Web of Science ®Google Scholar
• Matys V., Kel-Margoulis O. V., Fricke E., Liebich I., Land S., Barre-Dirrie A., Reuter I., Chekmenev D., Krull M., Hornischer K., Voss N., Stegmaier P., Lewicki-Potapov B., Saxel H., Kel A. E., Wingender E. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res. 2006; 34: D108–D110
   PubMed Web of Science ®Google Scholar
• McCarver D. G., Byun R., Hines R. N., Hichme M., Wegenek W. A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol. Appl. Pharmacol. 1998; 152: 276–281
   PubMed Web of Science ®Google Scholar
• McGlynn K. A., Rosvold E. A., Lustbader E. D., Hu Y., Clapper M. L., Zhou T., Wild C. P., Xia X. L., Baffoe-Bonnie A., Ofori-Adjei D. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc. Natl. Acad. Sci. USA 1995; 92: 2384–2387
   PubMed Web of Science ®Google Scholar
• McLemore T. L., Adelberg S., Liu M. C., McMahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A., Eggleston J. C., Boyd M. R., Hines R. N. Expression of CYP1A1 gene in patients with lung cancer: Evidence for cigarette smoke-induced expression in normal lung tissue and altered gene regulation in primary pulmonary carcinomas. J. Natl. Cancer Inst. 1990; 82: 1333–1339
   PubMed Web of Science ®Google Scholar
• McLeod H. L., Siva C. The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics 2002; 3: 89–98
   PubMed Web of Science ®Google Scholar
• McManus M. E., Burgess W. M., Veronese M. E., Huggett A., Quattrochi L. C., Tukey R. H. Metabolism of 2-acetylaminofluorene and benzo(a)pyrene and activation of food derived hertocyclic amine mutagens by human cytochromes P-450. Cancer Res. 1990; 50: 3367–3376
   PubMed Web of Science ®Google Scholar
• Miller K. K., Cai J., Ripp S. L., Pierce W. M., Jr., Rushmore T. H., Prough R. A. Stereo- and regioselectivity account for the diversity of dehydroepiandrosterone (DHEA) metabolites produced by liver microsomal cytochromes P450. Drug Metab. Dispos. 2004; 32: 305–313
   PubMed Web of Science ®Google Scholar
• Morel F., Rauch C., Coles B., Le F. E., Guillouzo A. The human glutathione transferase alpha locus: genomic organization of the gene cluster and functional characterization of the genetic polymorphism in the hGSTA1 promoter. Pharmacogenetics 2002; 12: 277–286
   PubMedGoogle Scholar
• Motulsky A. G. Drug reactions, enzymes and biochemical genetics. J. Amer. Med. Assn. 1957; 165: 835–837
   PubMed Web of Science ®Google Scholar
• Nakajima M., Komagata S., Fujiki Y., Kanada Y., Ebi H., Itoh K., Mukai H., Yokoi T., Minami H. Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet. Genomics 2007; 17: 431–445
   PubMed Web of Science ®Google Scholar
• Nakajima M., Yokoi T., Mizutani M., Kinoshita M., Funayama M., Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J. Biochem. (Tokyo) 1999; 125: 803–808
   PubMed Web of Science ®Google Scholar
• Nalla V. K., Rogan P. K. Automated splicing mutation analysis by information theory. Hum. Mutat. 2005; 25: 334–342
   PubMed Web of Science ®Google Scholar
• Nebert D. W. The Ah locus: Genetic differences in toxicity, cancer, mutation, and birth defects. Crit. Rev. Toxicol. 1989; 20: 153–174
   PubMed Web of Science ®Google Scholar
• Nebert D. W., Vasiliou V. Analysis of the glutathione S-transferase (GST) gene family. Hum. Genomics 2004; 1: 460–464
   PubMedGoogle Scholar
• Nomura F., Itoga S., Uchimoto T., Tomonaga T., Nezu M., Shimada H., Ochiai T. Transcriptional activity of the tandem repeat polymorphism in the 5′-flanking region of the human CYP2E1 gene. Alcohol Clin. Exp. Res. 2003; 27: 42S–46S
   PubMed Web of Science ®Google Scholar
• Oesch F., Glatt H., Schmassmann H. The apparent ubiquity of epoxide hydratase in rat organs. Biochem. Pharmacol. 1977; 26: 603–607
   PubMed Web of Science ®Google Scholar
• Okey A. B., Boutros P. C., Harper P. A. Polymorphisms of human nuclear receptors that control expression of drug-metabolizing enzymes. Pharmacogenet. Genomics 2005; 15: 371–379
   PubMed Web of Science ®Google Scholar
• Omiecinski C. J., Aicher L., Holubkov R., Checkoway H. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 1993; 3: 150–158
   PubMedGoogle Scholar
• Oneta C. M., Lieber C. S., Li J., Ruttimann S., Schmid B., Lattmann J., Rosman A. S., Seitz H. K. Dynamics of cytochrome P4502E1 activity in man: induction by ethanol and disappearance during withdrawal phase. J Hepatol. 2002; 36: 47–52
   PubMed Web of Science ®Google Scholar
• Ostanek B., Furlan D., Mavec T., Lukac-Bajalo J. UGT1A1(TA)n promoter polymorphism—a new case of a (TA)8 allele in Caucasians. Blood Cells Mol. Dis. 2007; 38: 78–82
   PubMed Web of Science ®Google Scholar
• Overby L. H., Carver G. C., Philpot R. M. Quantitation and kinetic properties of hepatic microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. Chem. Biol. Interact. 1997; 106: 29–45
   PubMed Web of Science ®Google Scholar
• Owens I. S., Basu N. K., Banerjee R. UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Meth. Enzymol. 2005; 400: 1–22
   PubMed Web of Science ®Google Scholar
• Owens I. S., Ritter J. K. The novel bilirubin/phenol UDP-glucuronosyltransferase UGT1 gene locus: implications for multiple nonhemolytic familial hyperbilirubinemia phenotypes. Pharmacogenetics 1992; 2: 93–108
   PubMedGoogle Scholar
• Parsey R. V., Hastings R. S., Oquendo M. A., Hu X., Goldman D., Huang Y. Y., Simpson N., Arcement J., Huang Y., Ogden R. T., Van Heertum R. L., Arango V., Mann J. J. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am. J. Psych. 2006; 163: 48–51
   PubMed Web of Science ®Google Scholar
• Pelkonen O., Rautio A., Raunio H., Pasanen M. CYP2A6: a human coumarin 7-hydroxylase. Toxicology 2000; 144: 139–147
   PubMed Web of Science ®Google Scholar
• Pemble S. E., Wardle A. F., Taylor J. B. Glutathione S-transferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue. Biochem. J. 1996; 319(Pt 3)749–754
   PubMed Web of Science ®Google Scholar
• Pitarque M., von R. O., Oke B., Berkkan H., Oscarson M., Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem. Biophys. Res. Commun. 2001; 284: 455–460
   PubMed Web of Science ®Google Scholar
• Pitarque M., von R. O., Rodriguez-Antona C., Wang J., Oscarson M., Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum. Mutat. 2004; 23: 258–266
   PubMed Web of Science ®Google Scholar
• Pollock B. G., Ferrell R. E., Mulsant B. H., Mazumdar S., Miller M., Sweet R. A., Davis S., Kirshner M. A., Houck P. R., Stack J. A., Reynolds C. F., Kupfer D. J. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000; 23: 587–590
   PubMed Web of Science ®Google Scholar
• Polonikov A. V., Ivanov V. P., Solodilova M. A., Khoroshaya I. V., Kozhuhov M. A., Panfilov V. I. Promoter polymorphism G-50T of a human CYP2J2 epoxygenase gene is associated with common susceptibility to asthma. Chest 2007; 132: 120–126
   PubMed Web of Science ®Google Scholar
• Qiu L. O., Linder M. W., Antonio-Green D. M., Valdes R., Jr. Suppression of cytochrome P450 2E1 promoter activity by interferon-g and loss of response due to the -71G>T nucleotide polymorphism of the CYP2E1*7B allele. J. Pharmacol. Exp. Ther. 2004; 308: 284–288
   PubMed Web of Science ®Google Scholar
• Raaka S., Hassett C., Omiecinski C. J. Human microsomal epoxide hydrolase: 5′-flanking region genetic polymorphisms. Carcinogenesis 1998; 19: 387–393
   PubMed Web of Science ®Google Scholar
• Rausch J. L., Johnson M. E., Fei Y. J., Li J. Q., Shendarkar N., Hobby H. M., Ganapathy V., Leibach F. H. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol. Psych. 2002; 51: 723–732
   PubMed Web of Science ®Google Scholar
• Rebbeck T. R., Jaffe J. M., Walker A. H., Wein A. J., Malkowicz S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 1998; 90: 1225–1229
   PubMed Web of Science ®Google Scholar
• Riedy M., Wang J. Y., Miller A. P., Buckler A., Hall J., Guida M. Genomic organization of the UGT2b gene cluster on human chromosome 4q13. Pharmacogenetics 2000; 10: 251–260
   PubMedGoogle Scholar
• Roberts-Thomson S. J., McManus M. E., Tukey R. H., Gonzalez F. J., Holder G. M. The catalytic activity of four expressed human cytochrome P450s towards benzo[a]pyrene and the isomers of its proximate carcinogen. Biochem. Biophys. Res. Commun. 1993; 192: 1373–1379
   PubMed Web of Science ®Google Scholar
• Rockman M. V., Wray G. A. Abundant raw material for cis-regulatory evolution in humans. Mol. Biol. Evol. 2002; 19: 1991–2004
   PubMed Web of Science ®Google Scholar
• Rogan P. K., Svojanovsky S., Leeder J. S. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics 2003; 13: 1–12
   PubMedGoogle Scholar
• Sachse C., Brockmoller J., Bauer S., Roots I. Functional significance of a C—>A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J Clin. Pharmacol. 1999; 47: 445–449
   PubMed Web of Science ®Google Scholar
• Saeki M., Saito Y., Jinno H., Tanaka-Kagawa T., Ohno A., Ozawa S., Ueno K., Kamakura S., Kamatani N., Komamura K., Kitakaze M., Sawada J. Single nucleotide polymorphisms and haplotype frequencies of UGT2B4 and UGT2B7 in a Japanese population. Drug Metab Dispos. 2004; 32: 1048–1054
   PubMed Web of Science ®Google Scholar
• Saito K., Moriya H., Sawaguchi T., Hayakawa T., Nakahara S., Goto A., Arimura Y., Imai K., Kurosawa N., Owada E., Miyamoto A. Haplotype analysis of UDP-glucuronocyltransferase 2B7 gene (UGT2B7) polymorphisms in healthy Japanese subjects. Clin. Biochem. 2006; 39: 303–308
   PubMed Web of Science ®Google Scholar
• Scarborough P. E., Ma J., Qu W., Zeldin D. C. P450 subfamily CYP2J and their role in the bioactivation of arachidonic acid in extrahepatic tissues. Drug Metab. Rev. 1999; 31: 205–234
   PubMed Web of Science ®Google Scholar
• Schuetz E.G., Beach D.L., Guzelian P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics 1994; 4: 11–20
   PubMedGoogle Scholar
• Seidegard J., DePierre J. W. Microsomal epoxide hydrolase. Properties, regulation and function. Biochim. Biophys. Acta 1983; 695: 251–270
   PubMed Web of Science ®Google Scholar
• Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 1994; 270: 414–423
   PubMed Web of Science ®Google Scholar
• Shintani M., Ieiri I., Inoue K., Mamiya K., Ninomiya H., Tashiro N., Higuchi S., Otsubo K. Genetic polymorphisms and functional characterization of the 5′-flanking region of the human CYP2C9 gene: In vitro and in vivo studies. Clin. Pharmacol. Ther. 2001; 70: 175–182
   PubMed Web of Science ®Google Scholar
• Shou M., Korzekwa K. R., Crespi C. L., Gonzalez F. J., Gelboin H. V. The role of 12 cDNA-expressed human, rodent, and rabbit cytochromes P450 in the metabolism of benzo[a]pyrene and benzo[a]pyrene trans-7,8-dihydrodiol. Mol. Carcinog. 1994; 10: 159–168
   PubMed Web of Science ®Google Scholar
• Sim S. C., Edwards R. J., Boobis A. R., Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet. Genomics 2005; 15: 625–631
   PubMed Web of Science ®Google Scholar
• Sim S. C., Risinger C., Dahl M. L., Aklillu E., Christensen M., Bertilsson L., Ingelman-Sundberg M. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin. Pharmacol. Ther. 2006; 79: 103–113
   PubMed Web of Science ®Google Scholar
• Smart J., Daly A. K. Variation in induced CYP1A1 levels: Relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics 2000; 10: 11–24
   PubMedGoogle Scholar
• Smeraldi E., Zanardi R., Benedetti F., Di Bella D., Perez J., Catalano M. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine. Mol. Psychiatry 1998; 3: 508–511
   PubMed Web of Science ®Google Scholar
• Smit P., van Schaik R. H., van der W. M., van den Beld A. W., Koper J. W., Lindemans J., Pols H. A., Brinkmann A. O., de Jong F. H., Lamberts S. W. A common polymorphism in the CYP3A7 gene is associated with a nearly 50% reduction in serum dehydroepiandrosterone sulfate levels. J Clin. Endocrinol. Metab 2005; 90: 5313–5316
   PubMed Web of Science ®Google Scholar
• Smits K. M., Smits L. J., Schouten J. S., Peeters F. P., Prins M. H. Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin. Ther. 2007; 29: 691–702
   PubMed Web of Science ®Google Scholar
• Smits K. M., Smits L. J., Schouten J. S., Stelma F. F., Nelemans P., Prins M. H. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol. Psychiatry 2004; 9: 433–441
   PubMed Web of Science ®Google Scholar
• Sophos N. A., Pappa A., Ziegler T. L., Vasiliou V. Aldehyde dehydrogenase gene superfamily: the 2000 update. Chem. Biol. Interact. 2001; 130–132: 323–337
   PubMed Web of Science ®Google Scholar
• Spiecker M., Darius H., Hankeln T., Soufi M., Sattler A. M., Schaefer J. R., Node K., Borgel J., Mugge A., Lindpaintner K., Huesing A., Maisch B., Zeldin D. C., Liao J. K. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation 2004; 110: 2132–2136
   PubMed Web of Science ®Google Scholar
• Spire-Vayron de la Moureyre, Debuysere H., Fazio F., Sergent E., Bernard C., Sabbagh N., Marez D., Lo Guidice J. M., D'halluin J. C., Broly F. Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics 1999; 9: 189–198
   PubMedGoogle Scholar
• Spire-Vayron de la Moureyre C., Debuysere H., Mastain B., Vinner E., Marez D., Lo Guidice J. M., Chevalier D., Brique S., Motte K., Colombel J. F., Turck D., Noel C., Flipo R. M., Pol A., Lhermitte M., Lafitte J. J., Libersa C., Broly F. Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br. J Pharmacol. 1998; 125: 879–887
   PubMed Web of Science ®Google Scholar
• Sugatani J., Yamakawa K., Yoshinari K., Machida T., Takagi H., Mori M., Kakizaki S., Sueyoshi T., Negishi M., Miwa M. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem. Biophys. Res. Commun. 2002; 292: 492–497
   PubMed Web of Science ®Google Scholar
• Takahashi H., Echizen H. Pharmacogenetics of warfarin elimination and its clinical complications. Clin. Pharmacokinet. 2001; 40: 587–603
   PubMed Web of Science ®Google Scholar
• Takahashi H., Ieiri I., Wilkinson G. R., Mayo G., Kashima T., Kimura S., Otsubo K., Echizen H. 5′-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood 2004; 103: 3055–3057
   PubMed Web of Science ®Google Scholar
• Takane H., Kobayashi D., Hirota T., Kigawa J., Terakawa N., Otsubo K., Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J. Pharmacol. Exp. Ther. 2004; 311: 1179–1187
   PubMed Web of Science ®Google Scholar
• Taniguchi S., Mochida Y., Uchiumi T., Tahira T., Hayashi K., Takagi K., Shimada M., Maehara Y., Kuwano H., Kono S., Nakano H., Kuwano M., Wada M. Genetic polymorphism at the 5′ regulatory region of multidrug resistance 1 (MDR1) and its association with interindividual variation of expression level in the colon. Mol. Cancer Ther. 2003; 2: 1351–1359
   PubMed Web of Science ®Google Scholar
• Tantcheva-Poor I., Zaigler M., Rietbrock S., Fuhr U. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131–144
   PubMedGoogle Scholar
• Thibaudeau J., Lepine J., Tojcic J., Duguay Y., Pelletier G., Plante M., Brisson J., Tetu B., Jacob S., Perusse L., Belanger A., Guillemette C. Characterization of common UGT1A8, UGT1A9, and UGT2B7 variants with different capacities to inactivate mutagenic 4-hydroxylated metabolites of estradiol and estrone. Cancer Res. 2006; 66: 125–133
   PubMed Web of Science ®Google Scholar
• Thomas S. S., Li S. S., Lampe J. W., Potter J. D., Bigler J. Genetic variability, haplotypes, and htSNPs for exons 1 at the human UGT1A locus. Hum. Mutat. 2006; 27: 717
   PubMed Web of Science ®Google Scholar
• Tukey R. H., Strassburg C. P. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581–616
   PubMed Web of Science ®Google Scholar
• Uchimoto T., Itoga S., Nezu M., Sunaga M., Tomonaga T., Nomura F. Role of the genetic polymorphisms in the 5′-flanking region for transcriptional regulation of the human CYP2E1 gene. Alcohol Clin. Exp. Res. 2007; 31: S36–S42
   PubMed Web of Science ®Google Scholar
• Ulrich C. M., Bigler J., Whitton J. A., Bostick R., Fosdick L., Potter J. D. Epoxide hydrolase Tyr113His polymorphism is associated with elevated risk of colorectal polyps in the presence of smoking and high meat intake. Cancer Epidemiol. Biomarkers Prev. 2001; 10: 875–882
   PubMed Web of Science ®Google Scholar
• Vasiliou V., Nebert D. W. Analysis and update of the human aldehyde dehydrogenase (ALDH) gene family. Hum. Genomics 2005; 2: 138–143
   PubMedGoogle Scholar
• Vasiliou V., Pappa A. Polymorphisms of human aldehyde dehydrogenases. Consequences for drug metabolism and disease. Pharmacology 2000; 61: 192–198
   PubMed Web of Science ®Google Scholar
• Veenstra D. L., Blough D. K., Higashi M. K., Farin F. M., Srinouanprachan S., Rieder M. J., Rettie A. E. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin. Pharmacol. Ther. 2005; 77: 353–364
   PubMed Web of Science ®Google Scholar
• Verlaan M., te Morsche R. H., Pap A., Laheij R. J., Jansen J. B., Peters W. H., Drenth J. P. Functional polymorphisms of UDP-glucuronosyltransferases 1A1, 1A6 and 1A8 are not involved in chronic pancreatitis. Pharmacogenetics 2004; 14: 351–357
   PubMedGoogle Scholar
• von Richter O., Pitarque M., Rodriguez-Antona C., Testa A., Mantovani R., Oscarson M., Ingelman-Sundberg M. Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6). Pharmacogenetics 2004; 14: 369–379
   PubMedGoogle Scholar
• Vyas P. M., Roychowdhury S., Koukouritaki S. B., Hines R. N., Krueger S. K., Williams D. E., Nauseef W. M., Svensson C. K. Enzyme-mediated protein haptenation of dapsone and sulfamethoxazole in human keratinocytes: II. Expression and role of flavin-containing monooxygenases and peroxidases. J Pharmacol. Exp. Ther. 2006; 319: 497–505
   PubMed Web of Science ®Google Scholar
• Vyhlidal C. A., Rogan P. K., Leeder J. S. Development and refinement of pregnane X receptor (PXR) DNA binding site model using information theory: insights into PXR-mediated gene regulation. J. Biol. Chem. 2004; 279: 46779–46786
   PubMed Web of Science ®Google Scholar
• Wang B., Ngoi S., Wang J., Chong S. S., Lee C. G. The promoter region of the MDR1 gene is largely invariant, but different single nucleotide polymorphism haplotypes affect MDR1 promoter activity differently in different cell lines. Mol. Pharmacol. 2006; 70: 267–276
   PubMed Web of Science ®Google Scholar
• Wang H., Faucette S., Sueyoshi T., Moore R., Ferguson S., Negishi M., LeCluyse E. L. A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol. Chem. 2003; 278: 14146–14152
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. Sulfotransferase pharmacogenetics. Pharmacol. Ther. 1990; 45: 93–107
   PubMed Web of Science ®Google Scholar
• Weinshilboum R. M., Sladek S. L. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980; 32: 651–662
   PubMed Web of Science ®Google Scholar
• Whalen R., Boyer T. D. Human glutathione S-transferases. Semin. Liver Dis. 1998; 18: 345–358
   PubMed Web of Science ®Google Scholar
• Williams J. A., Hyland R., Jones B. C., Smith D. A., Hurst S., Goosen T. C., Peterkin V., Koup J. R., Ball S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004; 32: 1201–1208
   PubMed Web of Science ®Google Scholar
• Wray G. A. The evolutionary significance of cis-regulatory mutations. Nat. Rev. Genet. 2007; 8: 206–216
   PubMed Web of Science ®Google Scholar
• Wrighton S. A., Stevens J. C., Becker G. W., Vandenbranden M. Isolation and characterization of human liver cytochrome P450 2C19: Correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys. 1993; 306: 240–245
   PubMed Web of Science ®Google Scholar
• Wu S., Moomaw C. R., Tomer K. B., Falck J. R., Zeldin D. C. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J. Biol. Chem. 1996; 271: 3460–3468
   PubMed Web of Science ®Google Scholar
• Xu P., Huang S. L., Zhu R. H., Han X. M., Zhou H. H. Phenotypic polymorphism of CYP2A6 activity in a Chinese population. Eur. J Clin. Pharmacol. 2002; 58: 333–337
   PubMed Web of Science ®Google Scholar
• Yamanaka H., Nakajima M., Katoh M., Hara Y., Tachibana O., Yamashita J., McLeod H. L., Yokoi T. A novel polymorphism in the promoter region of human UGT1A9 gene (UGT1A9*22) and its effects on the transcriptional activity. Pharmacogenetics 2004; 14: 329–332
   PubMedGoogle Scholar
• Yan L., Zhang S., Eiff B., Szumlanski C. L., Powers M., O'Brien J. F., Weinshilboum R. M. Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin. Pharmacol. Ther. 2000; 68: 210–219
   PubMed Web of Science ®Google Scholar
• Yeung C. K., Lang D. H., Thummel K. E., Rettie A. E. Immunoquantitation of FMO1 in human liver, kidney, and intestine. Drug Metab. Dispos. 2000; 28: 1107–1111
   PubMed Web of Science ®Google Scholar
• Yonan A. L., Palmer A. A., Gilliam T. C. Hardy-Weinberg disequilibrium identified genotyping error of the serotonin transporter (SLC6A4) promoter polymorphism. Psychiatr. Genet. 2006; 16: 31–34
   PubMed Web of Science ®Google Scholar
• Yoshida A., Rzhetsky A., Hsu L. C., Chang C. Human aldehyde dehydrogenase gene family. Eur. J. Biochem. 1998; 251: 549–557
   PubMedGoogle Scholar
• Yoshida R., Nakajima M., Nishimura K., Tokudome S., Kwon J. T., Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin. Pharmacol. Ther. 2003; 74: 69–76
   PubMed Web of Science ®Google Scholar
• Zanardi R., Serretti A., Rossini D., Franchini L., Cusin C., Lattuada E., Dotoli D., Smeraldi E. Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression. Biol. Psychiatry 2001; 50: 323–330
   PubMed Web of Science ®Google Scholar
• Zanger U. M., Klein K., Saussele T., Blievernicht J., Hofmann H., Schwab M. Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 2007; 8: 7437–59
   Web of Science ®Google Scholar
• Zukunft J., Lang T., Richter T., Hirsch-Ernst K. I., Nussler A. K., Klein K., Schwab M., Eichelbaum M., Zanger U. M. A natural CYP2B6 TATA box polymorphism (-82T—>C) leading to enhanced transcription and relocation of the transcriptional start site. Mol. Pharmacol. 2005; 67: 1772–1782
   PubMed Web of Science ®Google Scholar